[1]陆 兵,李明虎,文 宁,等.基于TCGA 和HPA 数据库生物学信息分析肝癌组织中YEATS2 表达水平与临床预后及治疗价值[J].现代检验医学杂志,2024,39(03):8-16.[doi:10.3969/j.issn.1671-7414.2024.03.002]
　LU Bing,LI Minghu,WEN Ning,et al.Analysis of YEATS2 Expression Level in Hepatocellular Carcinoma Tissues with Clinical Prognosis and Therapeutic Value Based on Biological Information from TCGA and HPA Databases[J].Journal of Modern Laboratory Medicine,2024,39(03):8-16.[doi:10.3969/j.issn.1671-7414.2024.03.002]
点击复制

基于TCGA 和HPA 数据库生物学信息分析肝癌组织中YEATS2 表达水平与临床预后及治疗价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年03期
页码:
8-16
栏目:
论著
出版日期:
2024-05-15

文章信息/Info

Title:
Analysis of YEATS2 Expression Level in Hepatocellular Carcinoma Tissues with Clinical Prognosis and Therapeutic Value Based on Biological Information from TCGA and HPA Databases
文章编号:
1671-7414（2024）03-008-09
作者:
陆 兵; 李明虎; 文 宁; 李海滨; 吴基华; 蓝柳根; 董建辉; 孙煦勇
（广西医科大学第二附属医院移植医学中心，广西器官移植临床医学研究中心，广西器官捐献与移植研究重点实验室，南宁 530007）
Author(s):
LU Bing; LI Minghu; WEN Ning; LI Haibin; WU Jihua; LAN Liugen; DONG Jianhui; SUN Xunyong
（Transplantation Medical Center，the Second Affiliated Hospital of Guangxi Medical University, Guangxi Organ Transplantation Clinical Medical Research Center , Guangxi Key Laboratory of Organ Donation and Transplantation, Nanning 530007，China）
关键词:
YEATS2; 肝细胞癌; 生物信息学; 预后分析; 肿瘤微环境
分类号:
R735.7；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.03.002
文献标志码:
A
摘要:
目的 基于肿瘤基因图谱（the cancer genome atlas，TCGA）和人类蛋白质图谱（human protein atlas，HPA）数据库生物学信息，分析肝细胞癌（hepatocellular carcinoma，HCC）中YEATS2 表达水平与临床预后及治疗价值。方法 从TCGA 数据库下载HCC 的mRNA 表达数据和临床资料，运用R 软件分析YEATS2 在HCC 组织与正常组织间的表达情况，并通过HPA 数据库对其蛋白表达差异进行初步验证。比较YEATS2 在HCC 各临床特征之间的表达差异，然后通过Kaplan-Meier 法和COX 回归分析评估其对HCC 患者生存期的影响，并绘制受试者工作特征（receiveroperating characteristic，ROC）曲线，评价其诊断价值。利用基因本体论（gene ontology，GO）和京都基因与基因组百科全书（Kyoto encyclopedia of genes and genomes，KEGG）富集分析，探讨YEATS2 在HCC 中的生物学功能。通过“ESTIMATE”算法分析YEATS2 表达与肿瘤微环境（tumor microenvironment，TME）的关系，并利用CIBERSORT 评估其与肿瘤浸润免疫细胞（tumor-infiltrating immune cells，TIICs）的相关性。利用R 包分析YEATS2 表达水平与免疫检查点及药物敏感度的关系。结果 在HCC 组织中YEATS2 的表达增加（P=4.96e-21），且表达水平与年龄、临床分期、病理分级和T 分期相关（均P ＜ 0.05）。YEATS2 高表达使HCC 患者的总生存率（overall survival，OS）（P<0.001)和无进展生存期（progression free survival，FPS）（P=0.016) 下降，COX 回归结果显示，YEATS2 表达水平与HCC 患者的不良预后相关（OS：HR=2.167，95%CI:1.441 ～ 3.261，P=2.06e-04），其是HCC 患者预测不良预后的独立危险因素（OS：HR=1.891，95%CI:1.243 ～ 2.877，P=0.003）。ROC 曲线提示：1，3，5 年AUC 分别为0.677，0.622 和0.612，具有良好预测能力。TCGA 数据库共筛选出YEATS2 高、低表达组的差异基因6 764 个，其中4 094 个基因在YEATS2高表达组中表达上调，2 670 个基因表达下调。GO 和KEGG 富集分析结果显示，YEATS2 高表达组差异基因主要富集在免疫调节、细胞周期调控和药物耐药等通路。TME 评分结果显示，YEATS2 高表达组引起免疫评分减少（P ＜ 0.01）。YEATS2 与TIICs 相关性显示，YEATS2 表达与M0 型巨噬细胞浸润水平呈正相关(r=0.48，P ＜ 0.001)，与CD8+T 细胞、浆细胞和单核细胞浸润水平呈负相关(r=-0.26，-0.29，-0.30，P=0.021，0.011，0.008)，并与23 种免疫检查点基因呈正相关（r=0.20 ～ 0.46，均P ＜ 0.05）。药物敏感度分析显示，YEATS2 高表达组患者中卡博替尼、林西替尼、多柔比星和环巴胺的半抑制浓度（half maximal inhibitory concentration，IC50）高于低表达组患者（均P ＜ 0.01）。结论 YEATS2 在HCC 中高表达，且表达水平与HCC 患者的预后不良有关。YEATS2 可作为HCC 临床早期诊断、预后和免疫治疗的生物标志物，为临床诊疗提供新的思路。
Abstract:
Objective To analyze the expression level of YEATS2 in hepatocellular carcinoma (HCC) about its clinical prognosis and therapeutic value based on biological information from the cancer genome atlas (TCGA) and human protein atlas (HPA) databases. Methods The mRNA expression data and clinical information of HCC were downloaded from the TCGA database, the expression of YEATS2 between HCC tissues and normal tissues was analyzed by using the R software, and the protein expression differences were preliminary verified by the HPA database. The expression differences of YEATS2 between various clinical features of HCC were compared, and their effects on the survival of HCC patients by Kaplan-Meier method and COX regression analysis were then evaluated. Receiver operating characteristic (ROC) curves were plotted to evaluate their diagnostic values. The biological functions of YEATS2 in HCC were analyzed using gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis. The relationship between YEATS2 expression and tumor microenvironment (TME) was analyzed by the “ESTIMATE”algorithm, and its relationship with tumor-infiltrating immune cells (TIICs) was assessed by CIBERSORT. Analysis of YEATS2 expression levels to immune checkpoints and drug sensitivity was performed using the R package. Results The expression of YEATS2 was increased in HCC tissues (P=4.96e-21), and its expression level was correlated with age, clinical stage, pathological grade and T stage (all P<0.05). Overall survival (OS) (P<0.001) and progression-free survival (FPS) (P=0.016) were decreased in HCC patients with high expression of YEATS2, COX regression results showed that the expression level of YEATS2 was associated with poor prognosis in HCC patients (OS: HR=2.167, 95%CI:1.441~3.261, P=2.06e-04), and it was an independent risk factor for predicting poor prognosis in HCC patients (OS: HR=1.891, 95% CI:1.243 ~2.877, P=0.003). The ROC curve suggested the AUCs for 1, 3 and 5 years were 0.677, 0.622 and 0.612, respectively, indicating good predictive ability. The TCGA database screened a total of 6 764 differential genes in the YEATS2 high and low expression groups, of which 4 094 genes were up-regulated and 2 670 genes were down-regulated in the YEATS2 high expression group. The results of GO and KEGG enrichment analyses showed that the differentially differentiated genes in the YEATS2 high expression group were mainly enriched in immunoregulation, and cell cycle regulation drug resistance pathway. The results of the TME score showed that the YEATS2 high expression group caused a decrease in immunity score (P<0.01). The correlation between YEATS2 and TIICs showed that YEATS2 expression was positively correlated with the level of M0-type macrophage infiltration levels (r=0.48，P<0.001) and 23 immune checkpoint genes (r=0.20 ～ 0.46, all P<0.05), and was negatively correlated with the CD8+T-cells, plasma cells and monocyte (r=-0.26， -0.29，-0.30，P=0.021，0.011，0.008). Drug sensitivity analysis showed that the half maximal inhibitory concentration (IC50) of cabozantinib, lincitinib, doxorubicin, and cyclobenzaprine in patients with high expression of YEATS2 was higher than those in patients with low expression (all P<0.01). Conclusion YEATS2 was highly expressed in HCC, and the expression level was associated with poor prognosis in HCC patients. YEATS2 can be used as a biomarker for the clinical early diagnosis, prognosis and immunotherapy of HCC, which may provide new ideas for clinical diagnosis and treatment.

参考文献/References:

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA-A Cancer Journal for Clinicians,2021, 71(3): 209-249.
[2] HLADY R A, SATHYANARAYAN A, THOMPSON J J, et al. Integrating the epigenome to identify drivers of hepatocellular carcinoma[J]. Hepatology, 2019, 69(2):639-652.
[3] ZHAO Dan, LI Yuanyuan, XIONG Xiaozhe, et al. YEATS domain-a histone acylation reader in health and disease[J]. Journal of Molecular Biology, 2017,429(13）: 1994-2002.
[4] ZHAO Dan, GUAN Haipeng, ZHAO Shuai, et al. YEATS2 is a selective histone crotonylation reader[J].Cell Research, 2016, 26(5）: 629-632.
[5] MI Wenyi, GUAN Haipeng, LYU Jie, et al. YEATS2 links histone acetylation to tumorigenesis of non-small cell lung cancer[J]. Nature Communications, 2017,8(1）: 1088.
[6] 李世超, 许文娟, 王玉兰. YEATS2 在肝细胞癌中的表达及临床意义[J]. 中国癌症防治杂志, 2020, 12(3): 297-302. LI Shichao, XU Wenjuan, WANG Yulan. Expression of YEATS2 in hepatocellular carcinoma and its clinical significance[J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 12(3): 297-302.
[7] HEINRICH S, CRAIG A J, MA Lichun, et al. Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis[J]. Journal of Hepatology, 2021,74(3): 700-715.
[8] SIA D, VILLANUEVA A, FRIEDMAN S L, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis[J]. Gastroenterology, 2017, 152(4):745-761.
[9] KENNEDY L B, SALAMA A K S. A review of cancer immunotherapy toxicity[J]. CA-A Cancer Journal for Clinicians, 2020, 70(2): 86-104.
[10] ROSATO P C, WIJEYESINGHE S, STOLLEY J M, et al. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy[J]. Nature Communications, 2019, 10(1): 567.
[11] PATEL D J, WANG Zhanxin. Readout of epigenetic modifications[J]. Annual Review of Biochemistry,2013, 82: 81-118.
[12] LUGER K, M?DER A W, RICHMOND R K, et al. Crystal structure of the nucleosome core particle at 2. 8 A resolution[J]. Nature, 1997, 389(6648): 251-260.
[13] WANG Yuanliang, FAIOLA F, XU Muyu, et al. Human ATAC is a GCN5/PCAF-containing acetylase complex with a novel NC2-like histone fold module that interacts with the TATA-binding protein[J]. Journal of Biological Chemistry, 2008, 283(49): 33808-33815.
[14] SHA Tong, LI Jia, SUN Shiqun, et al. YEATS domaincontaining 2 (YEATS2), targeted by microRNA miR-378a-5p, regulates growth and metastasis in head and neck squamous cell carcinoma[J]. Bioengineered, 2021,12(1): 7286-7296.
[15] ZENG Zhirui, LEI Shan, HE Zhiwei, et al. YEATS2 is a target of HIF1α and promotes pancreatic cancer cell proliferation and migration[J]. Journal of Cellular Physiology, 2021, 236(3): 2087-2098.
[16] SHENG Hao, ZHENG Fang, LAN Tian, et al. YEATS2 regulates the activation of TAK1/NF-κB pathway and is critical for pancreatic ductal adenocarcinoma cell survival[J]. Cell Biology and Toxicology, 2023, 39(3):1-16.
[17] LIU Xin, HU Yi, LI Cairong, et al. Overexpression of YEATS2 remodels the extracellular matrix to promote hepatocellular carcinoma progression via the PI3K/AKT pathway[J]. Cancers, 2023, 15(6): 1850.
[18] ZHANG Peng, TAN Xiaodong, ZHANG Daoqiang, et al. Development and validation of a set of novel and robust 4-lncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis[J]. PLoS One, 2021, 16(5): e0249951.
[19] ZHOU Jingyi, WANG Weiyu, LI Qi. Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages[J]. Journal of Experimental & Clinical Cancer Research, 2021, 40(1):73.
[20] 孙飞, 黎春明. 基于免疫细胞组织浸润的免疫评分模型预测前列腺癌免疫治疗效果及预后分析研究[J]. 现代检验医学杂志, 2023, 38(3): 189-194. SUN Fei,LI Chunming. Prediction of immunotherapy effect and prognosis of prostate cancer based on immune cell tissue infiltration immune score model [J].Journal of Modern Laboratory Medicine, 2023, 38(3):189-194.
[21] WANG Haiqiang, LU Xiyan, CHEN Jiakuan. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma[J]. BMC Medical Genomics, 2022, 15(1): 254.
[22] ZHANG Yiya, ZOU Ju, CHEN Ruochan. An M0 macrophage-related prognostic model for hepatocellular carcinoma[J]. BMC Cancer, 2022, 22(1): 791.
[23] CHEN Jianfei, WANG Rui, LIU Zhongliang, et al. Unbalanced glutamine partitioning between CD8 T+ cells and cancer cells accompanied by immune cell dysfunction in hepatocellular carcinoma[J]. Cells. 2022, 11(23): 3924.
[24] LI Bin, CHAN H L, CHEN Pingping. Immune checkpoint inhibitors: basics and challenges[J]. Current Medicinal Chemistry, 2019, 26(17): 3009-3025.
[25] CHANG H, JUNG W, KIM A, et al. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma[J]. APMIS, 2017, 125(8): 690-698.
[26] DAI Xiaomeng, XUE Jun, HU Jianli, et al. Positive expression of programmed death ligand 1 in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma[J].Translational Oncology, 2017, 10(4): 511-517.
[27] HUANG Poshuan, WANG Lingyu, WANG Yiwen, et al. Evaluation and application of drug resistance by biomarkers in the clinical treatment of liver cancer[J].Cells, 2023, 12(6): 869.
[28] ESTEBAN-FABR? R, WILLOUGHBY C E, PIQU?-GILI M, et al. Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma[J]. Clinical Cancer Research,2022, 28(11): 2449-2460.
[29] GUO Yu, MEHRABI NASAB E, HASSANPOUR F,et al. Linsitinib and aspirin as the IGF1-R antagonists,inhibit regorafenib-resistant chemotherapy in colon cancer[J]. Saudi Journal of Biological Sciences, 2022,29(2): 872-877.
[30] KHAN S, LEBLANC R, GYGER M, et al. A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma[J]. Leukemia & Lymphoma, 2021, 62(7): 1721-1729.
[31] CHEN Yang, ZENG Linyuan, ZHU Hongzhang, et al. Ferritin nanocaged doxorubicin potentiates chemoimmunotherapy against hepatocellular carcinoma via immunogenic cell death[J]. Small Methods, 2023, 7(5):e2201086.
[32] PENG Zhipeng, HUANG Shanfu, LI Junjun, et al. The effects of hedgehog signaling pathway on the proliferation and apoptosis of melanoma cells[J].Journal of Oncology, 2022, 2022: 4984866.

相似文献/References:

[1]邓旭,王晓亮.肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义[J].现代检验医学杂志,2015,30(06):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
　DENG Xu,WANG Xiao-liang.Expression and Clinical Significance of Serum CXCR12 and SA in Patients with Hepatocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(03):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
[2]毛丽萍,何义民,韩 刚,等.血浆Dickkopf同源物1检测对肝细胞癌的诊断价值[J].现代检验医学杂志,2016,31(05):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
　MAO Li-ping,HE Yi-min,HAN Gang,et al.Diagnosis Value of Detecting Plasma Dickkopf-1 Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(03):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
[3]阮瑞杨,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
　RUAN Rui-yang,CHEN Xiu-rong,ZHAO Shi-yuan.Expression and Significance of Anti EZH2 Autoantibodies IgG in Hepatocellular Carcinoma Patient's Serum Samples[J].Journal of Modern Laboratory Medicine,2017,32(03):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
[4]隆绍平,邓世群,赵世元.PTPN12蛋白表达下调与原发性肝细胞癌患者复发和预后关系研究[J].现代检验医学杂志,2018,33(01):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　LONG Shao-ping,DENG Shi-qun,ZHAO Shi-yuan.Association between Downregulation of PTPN12 Protein and Recurrence and Prognosis in Patients with Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(03):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[5]毛丽萍,王跃国,王 健,等.CMIA法测定血清DCP与AFP对肝细胞癌的诊断价值[J].现代检验医学杂志,2018,33(06):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
　MAO Li-ping,WANG Yue-guo,WANG Jian,et al.Diagnostic Value of the Serum DCP and AFP Determined by CMIA in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(03):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
[6]吴良银a,李文丽b,刘 俊a.肝细胞癌患者生存预后相关长链非编码RNA(LncRNA)的生物信息学分析[J].现代检验医学杂志,2019,34(04):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
　WU Liang-yina,LI Wen-lib,LIU Juna.Bioinformatics Analysis of Long-Chain Non-Coding RNA Related to Survival and Prognosis in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2019,34(03):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
[7]吴良银a,李文丽b,刘　俊b.基于GEO数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J].现代检验医学杂志,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
　WU Liang-yin,LI Wen-li,LIU Jun.Screening and Bioinformatics Analysis of Potential Biomarkers for Virus-associated Hepatocellular Carcinoma Based on GEO Data[J].Journal of Modern Laboratory Medicine,2021,36(03):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
[8]陈 偲,李忠辉a,王 颖b.miR-198 通过靶向ZEB2 调控EMT 过程抑制肝癌细胞增殖和迁移的机制研究[J].现代检验医学杂志,2022,37(04):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
　CHEN Si,LI Zhong-huia,WANG Yingb.Study on the Mechanism of miR-198 Inhibiting the Proliferation and Migration of Hepatoma Cells by Regulating EMT Process by Targeting ZEB2[J].Journal of Modern Laboratory Medicine,2022,37(03):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
[9]王 路,叶 莎,韩 霞,等.循环外泌体miRNA 检测对肝细胞癌临床诊断效能的Meta 分析[J].现代检验医学杂志,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
　WANG Lu,YE Sha,HAN Xia,et al.Meta-Analysis of the Diagnostic Value of Circulating Exosomes miRNA Detection for Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(03):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[10]时晓晓a,董 翔a,于若卉b,等.miR-203a-3p 靶向GLS1 调控HCC 细胞增殖、迁移、侵袭的机制研究[J].现代检验医学杂志,2022,37(05):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
　SHI Xiao-xiaoa,DONG Xianga,YU Ruo-huib,et al.Mechanism of miR-203a-3p Targeting GLS1 to Regulate the Proliferation, Migration and Invasion of HCC Cells[J].Journal of Modern Laboratory Medicine,2022,37(03):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]

备注/Memo

备注/Memo:
基金项目： 广西医学高层次骨干人才培养“139”计划培养项目（G202002016）；广西自然科学基金区域高发疾病研究联合专项资助（项目任务书编号：2023GXNSFAA026142）。
作者简介：陆兵（1995-），男，硕士在读，研究方向：器官捐献与移植基础及临床研究，E-mail:184494880@qq.com。
通讯作者： 孙煦勇（1970-），男，博士，主任医师，研究方向：器官捐献与移植基础及临床研究，移植免疫学，E-mail:sxywn@sohu.com。
更新日期/Last Update: 2024-05-15